Indevus reports positive Nebido trial data

Lexington drug company Indevus Pharmaceuticals Inc. reported positive data today from a trial of Nebido, a testosterone therapy under development for the treatment of male hypogonadism.

According to Indevus, male hypogonadism is an increasingly recognized medical condition characterized by a reduced or absent secretion of testosterone from the testes; common effects of hypogonadism include decreased sexual desire, muscle loss and weakness, and increased risk of osteoporosis.

In disclosing final results from its Phase III pharmacokinetic trial, the company said that Nebido achieved "all key endpoints for both efficacy and safety."

Indevus describes Nebido as "a long-acting injectable testosterone therapy for the treatment of male hypogonadism," which is licensed from Bayer Schering Pharma AG of Germany.
(By Chris Reidy, Globe staff)